title: Benign liver tumors in children: a 25-year experience.
abstract: The most common benign liver tumors are hemangiomas and hamartomas, both of mesenchymal origin. Mortality for patients with these tumors has traditionally been substantial despite benign histology. Between 1965 and 1989, 22 patients were treated for a benign liver tumor. This represents 42% of all primary neoplasms of the liver observed during this period. Incidental findings of liver tumors at autopsy were excluded from this series. There were 9 boys and 13 girls with a mean age at presentation of 2.3 years (range, birth to 14 years). Sixteen had hemangiomas and presented earlier in life (mean age, 4.4 months). In this subgroup, high-output cardiac failure was present in 58% of the newborns. Seven hemangiomas were resected, four were observed, three were treated with digitalis, diuretics, and steroids, and one received epsilon-aminocaproic acid. Nonhemangiomatous tumors included four hamartomas, one focal nodular hyperplasia, and one nodular transformation. All six were resected. There was one death early in the series. At a mean follow-up of 38 months, 21 of the 22 patients are cured or asymptomatic. In the past, mortality rates of close to 90% have prompted many investigators to advocate resection of every symptomatic hemangioma. With the availability of more sophisticated imaging techniques and refinements in the treatment of cardiac failure, surgery can be used more selectively. Hepatic resections, once considered heroic, can now be performed with minimal morbidity and virtually no mortality. The 96% survival in this series of benign liver tumors contrasts with high mortality rates reported in the literature and illustrates the spectacular improvements that have been made in the diagnosis and management of these once ill-reputed tumors.
authors.affiliation: Department of Surgery, Hôpital Sainte-Justine, Montreal, Quebec, Canada.
authors.forename: F I
authors.initials: FI
authors.lastname: Luks
authors.forename: S
authors.initials: S
authors.lastname: Yazbeck
authors.forename: M L
authors.initials: ML
authors.lastname: Brandt
authors.forename: A L
authors.initials: AL
authors.lastname: Bensoussan
authors.forename: P
authors.initials: P
authors.lastname: Brochu
authors.forename: H
authors.initials: H
authors.lastname: Blanchard
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006222:Hamartoma / Q000401:mortality* / Q000601:surgery; D006391:Hemangioma / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D006801:Humans; D006965:Hyperplasia / Q000401:mortality / Q000601:surgery; D007223:Infant; D007231:Infant, Newborn; D008099:Liver / Q000473:pathology* / Q000601:surgery; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D008297:Male; D012189:Retrospective Studies; D015996:Survival Rate